AbbVie Inc. (ABBV): Price and Financial Metrics

AbbVie Inc. (ABBV): $141.99

3.67 (+2.65%)

POWR Rating

Component Grades














  • Quality is the dimension where ABBV ranks best; there it ranks ahead of 97.76% of US stocks.
  • The strongest trend for ABBV is in Quality, which has been heading up over the past 179 days.
  • ABBV ranks lowest in Momentum; there it ranks in the 11th percentile.

ABBV Stock Summary

  • ABBVIE INC's market capitalization of $237,296,230,594 is ahead of 99.51% of US-listed equities.
  • ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 90.62% of US stocks.
  • The volatility of ABBVIE INC's share price is greater than that of only 8.54% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to ABBV, based on their financial statements, market capitalization, and price volatility, are NVO, BABA, PFE, TMO, and DHR.
  • ABBV's SEC filings can be seen here. And to visit ABBVIE INC's official web site, go to

ABBV Valuation Summary

  • In comparison to the median Healthcare stock, ABBV's price/earnings ratio is 2.04% higher, now standing at 20.
  • Over the past 118 months, ABBV's EV/EBIT ratio has gone up 4.4.

Below are key valuation metrics over time for ABBV.

Stock Date P/S P/B P/E EV/EBIT
ABBV 2022-09-23 4.4 17.3 20.0 19.5
ABBV 2022-09-22 4.4 17.3 20.0 19.5
ABBV 2022-09-21 4.3 16.9 19.6 19.2
ABBV 2022-09-20 4.4 17.1 19.8 19.3
ABBV 2022-09-19 4.4 17.2 20.0 19.4
ABBV 2022-09-16 4.4 17.4 20.2 19.6

ABBV Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 706.71%.
  • The 4 year net income to common stockholders growth rate now stands at 41.71%.
  • The 3 year cash and equivalents growth rate now stands at 24.53%.
ABBV's revenue has moved up $7,154,000,000 over the prior 15 months.

The table below shows ABBV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 57,349 22,923 12,637
2022-03-31 56,725 22,808 12,479
2021-12-31 56,197 22,777 11,542
2021-09-30 55,169 22,556 7,534
2021-06-30 53,729 20,451 6,663
2021-03-31 50,195 18,650 5,159

ABBV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABBV has a Quality Grade of B, ranking ahead of 80.75% of graded US stocks.
  • ABBV's asset turnover comes in at 0.369 -- ranking 131st of 682 Pharmaceutical Products stocks.
  • PLXP, HSTO, and ADMP are the stocks whose asset turnover ratios are most correlated with ABBV.

The table below shows ABBV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.369 0.677 0.119
2021-06-30 0.359 0.656 0.102
2021-03-31 0.335 0.648 0.078
2020-12-31 0.339 0.664 0.070
2020-09-30 0.339 0.687 0.131
2020-06-30 0.372 0.736 0.147

ABBV Stock Price Chart Interactive Chart >

Price chart for ABBV

ABBV Price/Volume Stats

Current price $141.99 52-week high $175.91
Prev. close $138.32 52-week low $106.86
Day low $137.76 Volume 6,612,300
Day high $142.72 Avg. volume 6,874,867
50-day MA $140.88 Dividend yield 3.97%
200-day MA $146.38 Market Cap 251.05B

AbbVie Inc. (ABBV) Company Bio

Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.

ABBV Latest News Stream

Event/Time News Detail
Loading, please wait...

ABBV Latest Social Stream

Loading social stream, please wait...

View Full ABBV Social Stream

Latest ABBV News From Around the Web

Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

Five Expected Dividend Increases In October 2022

Every month we feature the expected dividend increases set to occur that month. Why? Since we are passionate dividend investors, we love seeing our dividend income grow without lifting a finger. Hence why we are always on the lookout for upcoming dividend increases. This article will discuss 5 expected dividend increases in October 2022.

Why Dividend Increases Matter

Dividends are the foundation of our goal to reach financial freedom. We continuously invest in dividend growth stocks to grow our passive income. If you haven’t figured it out by now, we eat, sleep, and breathe dividends.

If the goal is to produce a passive income stream that will one day cover our expenses, making sure that income stream grows is critical. Without growth, your dividend income ...

Dividend Diplomats on Seeking Alpha | October 4, 2022

5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why

Based on Monday's view of an IBD-produced screen, they now include small-cap enterprise software firm Model N, lithium metal producer Albemarle, electrical equipment firm Hubbell and trendy footwear and apparel firm Deckers Outdoor. In 2022, the NYSE's composite index continues to outperform its Nasdaq sibling. Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.

Yahoo | October 3, 2022

Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?

AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.

Yahoo | October 3, 2022

Bear Market Bargains: 3 Dividend Stocks to Buy Now

All three of these stocks are attractively valued even though they're beating the market this year.

Yahoo | October 3, 2022

Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

With the market down by more than 21% in 2022, we're officially in a bear market, and many investors are scrambling to protect themselves. AbbVie's (NYSE: ABBV) stock is up 9.9% this year, and with a bunch of recently reported clinical trial results and green lights from regulators, it isn't too surprising why. Most recently, on Sept. 10, it announced that a pair of its phase 3 trials of Skyrizi, a psoriatic arthritis drug that's already on the market, showed that the drug was performing favorably in long-term followup studies.

Yahoo | October 2, 2022

Read More 'ABBV' Stories Here

ABBV Price Returns

1-mo N/A
3-mo -5.71%
6-mo -17.39%
1-year 34.97%
3-year 119.49%
5-year 97.29%
YTD 7.86%
2021 32.43%
2020 27.72%
2019 1.47%
2018 -0.96%
2017 60.08%

ABBV Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABBV Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7757 seconds.